malaria
continu
caus
diseas
million
human
annual
death
toll
approxim
per
year
malaria
infect
caus
plasmodia
parasit
complex
life
cycl
stage
vertebr
invertebr
host
five
speci
plasmodium
infecti
human
plasmodium
falciparum
plasmodium
vivax
plasmodium
malaria
plasmodium
oval
plasmodium
knowlesi
p
falciparum
respons
major
death
caus
malaria
p
vivax
recent
shown
caus
approxim
sever
malaria
southeast
asia
multidrug
resist
p
vivax
identifi
infect
human
begin
human
bitten
infect
femal
anophel
mosquito
inocul
sporozoit
dermi
sporozoit
subsequ
travel
blood
invad
hepatocyt
liverstag
ls
parasit
separ
infect
hepatocyt
select
parasitophor
vacuolar
membran
pvm
host
hepatocyt
plasma
membran
origin
grow
ls
parasit
acquir
nutrient
host
hepatocyt
time
prevent
apoptosi
infect
hepatocyt
gener
ten
thousand
merozoit
subsequ
ruptur
liver
start
pathogen
blood
stage
infect
main
sporozoit
antigen
cover
entir
sporozoit
surfac
circumsporozoit
protein
csp
csp
still
main
target
vaccin
trial
last
sever
decad
mainli
antigen
domain
sporozoit
neutral
effect
cspantibodi
vitro
vivo
advanc
subunit
malaria
vaccin
rt
base
repeat
region
csp
coupl
hepat
b
envelop
protein
potent
adjuv
rt
induc
impress
csp
antibodi
respons
result
vaccin
efficaci
clinic
malaria
children
efficaci
infant
month
follow
immun
antibodi
respons
significantli
wane
time
protect
vaccin
method
led
longlast
complet
steril
protect
malaria
parasit
challeng
anim
control
human
malaria
infect
chmi
immun
live
irradiationattenu
sporozoit
field
studi
burkina
faso
mali
kenya
gabon
tanzania
current
follow
approach
studi
import
effort
develop
effect
malaria
vaccin
attenu
irradi
easili
standard
human
use
overirradi
sporozoit
confer
littl
protect
underirradi
provid
risk
breakthrough
infect
recent
attenu
sporozoit
conduct
target
delet
gene
encod
ls
essenti
protein
mous
model
attenu
model
plasmodium
sporozoit
invad
hepatocyt
within
vacuol
ceas
growth
complet
caus
plasmodium
infect
blood
protect
confer
attenu
sporozoit
confirm
mainli
mediat
cell
target
ls
antigen
antigen
present
surfac
migrat
sporozoit
recent
studi
point
compar
attenu
strain
ceas
ls
develop
earli
attenu
strain
grow
longer
hepatocyt
ceas
growth
led
signific
protect
immun
respons
indic
signific
exposur
ls
antigen
enhanc
vaccin
effect
liverassoci
cell
implic
antimalari
immun
follow
irradi
sporozoit
vaccin
cell
lack
cell
surfac
marker
highli
express
liverinfiltr
cell
reduct
liverassoci
memori
sporozoit
immun
recent
studi
includ
report
support
tissu
resid
memori
cell
appear
import
target
ls
malaria
follow
vaccin
appear
ls
antigen
repres
import
candid
induc
protect
cell
respons
attenu
sporozoit
model
despit
evid
potenti
live
attenu
parasit
vaccin
feasibl
largescal
applic
live
attenu
sporozoit
produc
asept
mosquito
high
amount
still
develop
altern
vaccin
platform
remain
interest
hypothes
vaccin
compris
multipl
ls
antigen
deliv
optim
synthet
dna
plasmid
cassett
might
induc
protect
immun
similar
observ
live
attenu
parasit
model
focus
follow
antigen
express
across
plasmodia
pfn
icp
export
protein
glutathion
transferas
locat
parasitehost
interfac
effici
degrad
cytotox
hematin
associ
metabol
suscept
artesun
frontlin
antimalari
drug
addit
shown
contain
degener
cell
epitop
previous
shown
immunogen
mous
model
malaria
evid
human
may
import
antimalari
target
posit
antibodi
respons
correl
statist
signific
decreas
malari
infect
children
burkina
faso
pfn
profilin
detect
life
cycl
stage
includ
sporozoit
merozoit
abund
pfn
express
suggest
pfn
import
plasmodium
life
cycl
progress
like
apicomplexan
plasmodium
util
highli
special
microfila
system
motil
host
cell
invas
profilin
play
key
role
actinsequest
protein
shown
disturb
express
pfn
result
complet
life
cycl
arrest
similarli
export
protein
integr
vacuolar
protein
resid
primarili
vacuolar
face
pvm
like
constitut
membran
pore
plasmodium
icp
inhibitor
cystein
proteas
shown
necessari
malaria
transmiss
mosquito
mammal
sporozoit
motil
erythrocyt
invas
liverstag
develop
littl
known
transmembran
protein
vaccin
reduc
liverstag
parasit
load
mous
model
shown
contribut
protect
immun
elicit
whole
parasit
vaccin
antigen
upregul
infect
membran
protein
local
pvm
infect
hepatocyt
interact
directli
host
liverfatti
acid
bind
protein
lfabp
essenti
earli
liverstag
develop
vaccin
vaccin
contain
shown
partial
protect
mous
model
one
strength
synthet
dna
vaccin
platform
eas
antigen
coformul
molecular
adjuv
clinic
given
focu
induct
cellular
immun
explor
use
synthet
dnaencod
plasmid
uniqu
molecular
adjuv
member
famili
although
origin
associ
immun
also
report
facilit
gener
protect
cell
immun
immunoadjuv
effect
hpvassoci
model
cancer
immunotherapi
cellmedi
immun
critic
protect
report
enhanc
potent
antigenspecif
effector
memori
tcell
immun
synthet
dna
vaccin
set
abil
induc
potent
cellmedi
immun
import
vaccin
ls
malaria
fact
predominantli
express
epitheli
barrier
first
line
defens
pathogen
threat
activ
varieti
import
immun
cell
may
relev
necess
plasmodium
sporozoit
transvers
dermi
ls
infect
consequ
chosen
molecular
adjuv
studi
anoth
strength
dna
vaccin
platform
abil
drive
function
local
cellmedi
immun
cmi
clinic
prior
work
studi
immun
hepat
b
dna
vaccin
show
abil
platform
drive
vaccinespecif
ctl
traffic
liver
organ
known
tolerogen
suppress
cell
respons
abil
platform
drive
vaccinespecif
ctl
locat
highlight
potenti
drive
relev
function
cmi
context
protein
sequenc
select
plasmodium
antigen
access
plasmodb
plasmodium
genom
resourc
pfn
icp
antigen
select
express
across
plasmodia
vaccin
construct
match
plasmodium
yoelii
py
reflect
plan
challeng
model
p
yoelii
nonleth
strain
synthet
dna
vaccin
construct
codon
optim
mice
human
incorpor
modifi
pvax
vector
ige
leader
sequenc
ha
tag
indic
figur
order
assess
vitro
express
vaccin
construct
cell
plate
plate
cell
per
well
ml
dmem
gibco
fb
incub
overnight
cell
transfect
dna
use
turbofectin
transfect
kit
incub
h
transfect
supernat
lysat
collect
western
blot
analysi
sampl
prepar
nupag
ld
sampl
buffer
reduc
agent
deioniz
water
sampl
mixtur
incub
min
volum
sampl
load
per
well
onto
invitrogen
nupag
bistri
gel
nupag
mop
run
buffer
gel
run
v
min
protein
transfer
methanol
activ
pvdf
membran
use
iblot
dri
blot
system
life
technolog
carlsbad
ca
usa
membran
block
h
room
temperatur
licor
odyssey
block
buffer
follow
overnight
incub
primari
antibodi
primari
antibodi
either
antiha
antibodi
thermofish
waltham
usa
detect
express
construct
contain
ha
tag
postimmun
sera
collect
immun
mice
detect
express
construct
ha
tag
wash
membran
incub
h
room
temperatur
irdy
label
secondari
antibodi
licor
imag
use
odyssey
clx
imag
femal
balbcj
mice
order
jackson
laboratori
age
week
hous
wistar
institut
anim
facil
anim
handl
conduct
accord
approv
protocol
institut
anim
care
use
committe
iacuc
wistar
institut
protocol
mice
immun
dna
vaccin
construct
without
plasmid
deliv
intramuscularli
use
cellectra
adapt
constant
current
electropor
mice
immun
cocktail
antigen
dna
vaccin
construct
use
depend
experi
mice
immun
time
week
interv
blood
collect
week
post
vaccin
sera
isol
one
week
post
final
immun
mice
euthan
splenocyt
hepatocyt
collect
immun
analysi
euthanasia
liver
spleen
tissu
remov
immun
cell
isol
liver
excis
hepat
portal
vein
exit
liver
cut
ml
cold
pb
solut
administ
left
ventricl
profus
liver
blanch
perfus
liver
remov
place
cold
complet
media
dmem
fb
mm
hepe
penstrep
liver
quickli
homogen
min
normal
speed
use
stomach
seward
homogen
transfer
plate
ml
digest
media
dmem
mm
hepe
mgml
collagenas
mgml
dnase
ad
plate
incub
min
cell
filter
mesh
strainer
rins
pb
centrifug
rpm
min
supernat
contain
hepatocyt
transfer
new
tube
spun
min
rpm
cell
pellet
resuspend
percol
sigmaaldrich
st
loiu
mo
usa
underlaid
percol
spun
rpm
min
slow
acceler
deceler
hepatocyt
interfac
two
percol
layer
remov
dilut
complet
media
count
use
countess
ii
invitrogen
carlsbad
ca
usa
trypan
blue
gibco
spleen
remov
place
rpmi
fb
penstrep
spleen
homogen
min
high
use
stomach
cell
solut
filter
strainer
spun
min
rpm
cell
resuspend
ml
ack
lysi
buffer
gibco
incub
min
wash
pb
cell
spun
min
rpm
splenocyt
resuspend
ml
count
mous
elispot
plu
mabtech
cincinnati
oh
usa
plate
use
direct
briefli
plate
wash
pb
block
min
well
seed
triplic
cell
cell
stimul
peptid
pool
overlap
amino
acid
span
entir
vaccin
antigen
final
concentr
per
peptid
concanavalin
use
neg
posit
control
respect
plate
incub
h
plate
develop
direct
scan
count
use
ctl
immunospot
univers
analyz
data
export
microsoft
excel
graphpad
prism
analysi
well
seed
cell
cell
stimul
peptid
final
concentr
per
peptid
presenc
protein
transport
inhibitor
ebiosci
san
diego
ca
usa
cell
stimul
cocktail
ebiosci
san
diego
ca
usa
use
neg
posit
control
respect
plate
incub
h
follow
incub
cell
wash
pb
stain
livedead
fixabl
aqua
dead
cell
stain
kit
thermofish
waltham
usa
pb
cell
stain
extracellular
marker
fac
buffer
fb
pb
fix
permeabil
bd
fixperm
stain
intracellular
marker
cytokin
bd
permwash
resuspend
fac
buffer
run
bd
lsrii
flow
cytomet
bd
bioscienc
franklin
lake
nj
usa
splenocyt
hepatocyt
stain
follow
panel
livedead
aqua
invitrogen
carlsbad
ca
usa
bdhorizon
franklin
lake
nj
usa
biolegend
san
diego
ca
usa
bd
pharmingen
franklin
lake
nj
usa
biolegend
san
diego
ca
usa
biolegend
san
diego
ca
usa
ebiosci
san
diego
ca
usa
ebiosci
san
diego
ca
usa
biolegend
san
diego
ca
usa
gate
set
use
fmo
stain
data
export
analyz
graphpad
prism
cell
cell
line
deriv
mous
liver
cell
plate
precoat
polydlysin
corn
chamber
well
cell
per
well
dmem
gibco
fb
incub
overnight
cell
transfect
dna
use
thermofish
lipofectamin
transfect
kit
incub
h
media
remov
cell
wash
twice
pb
gibco
min
fix
pfa
pb
min
cell
wash
twice
pb
follow
block
goat
serum
h
room
temperatur
follow
two
min
pb
wash
cell
incub
pool
mous
sera
dilut
dilut
buffer
bsa
pb
room
temp
h
wash
three
time
pbst
pb
min
cell
incub
secondari
antibodi
dilut
dilut
buffer
room
temp
h
cell
wash
pbst
min
incub
dapi
hoechst
fluoresc
stain
thermo
scientif
waltham
usa
dilut
pbst
min
follow
final
wash
pbst
cell
imag
use
leica
tc
confoc
microscop
sixtoeightweekold
femal
swiss
webster
sw
mice
purchas
envigo
indianapoli
usa
use
mosquito
feed
experi
gener
salivari
gland
sporozoit
challeng
studi
anim
handl
conduct
accord
approv
protocol
institut
anim
care
use
committe
iacuc
tulan
univers
protocol
mosquito
feed
experi
conduct
p
yoelii
wildtyp
parasit
previous
describ
briefli
sw
mice
treat
phenylhydrazin
inject
intraven
million
blood
stage
parasit
day
post
infect
exflagel
assay
use
confirm
avail
format
p
yoelii
male
microgamet
mosquito
feed
conduct
allow
femal
mosquito
feed
mous
anesthet
ketaminexylazin
min
salivari
gland
sporozoit
extract
conduct
dissect
salivari
gland
infect
femal
mosquito
day
post
mosquito
feed
pmf
rpmi
incomplet
medium
previous
describ
collect
salivari
gland
mechan
disrupt
pestl
salivari
gland
sporozoit
count
use
hemocytomet
dose
sporozoit
incomplet
rpmi
prepar
previous
describ
sixtoeightweekold
femal
balbcj
mice
purchas
jackson
laboratori
bar
harbor
use
challeng
experi
mice
put
red
heat
lamp
min
inject
dose
sporozoit
load
insulin
syring
inject
intraven
tail
vein
immun
mice
giemsastain
thin
blood
smear
check
everi
day
least
whole
microscopi
field
blood
stage
parasit
start
day
day
post
infect
previous
identifi
ls
protein
optim
encod
modifi
pvax
plasmid
plasmid
contain
ige
leader
sequenc
gene
sequenc
linker
sequenc
pfn
gene
sequenc
plasmid
contain
ige
leader
sequenc
gene
sequenc
icp
respect
ha
tag
figur
ls
protein
select
express
across
plasmodia
synthet
optim
dna
vaccin
construct
match
plasmodium
yoelii
py
reflect
plan
challeng
model
vitro
express
py
construct
transfect
lysat
detect
western
blot
express
confirm
plasmid
detect
ha
tag
express
plasmid
lack
ha
tag
confirm
probe
postimmun
sera
mice
immun
construct
gfp
transfect
use
neg
control
figur
assess
cellular
immun
respons
ls
antigen
vaccin
group
five
mice
immun
time
interv
one
five
construct
individu
empti
vector
pvax
one
week
final
immun
splenocyt
collect
immun
analysi
antigenspecif
cytokin
product
assess
elispot
flow
cytometri
five
construct
induc
detect
cellular
respons
icp
highest
induc
induc
lower
still
robust
level
secret
cell
induc
readili
detect
lowest
level
secret
cell
figur
function
profil
antigenspecif
figur
figur
cell
analyz
flow
cytometri
mono
doubl
tripleposit
cell
releas
cytokin
shown
cell
respond
highli
icp
contrast
cell
respond
highli
pfn
expect
elispot
flow
cytometri
respons
mice
immun
empti
vector
control
pvax
neglig
figur
investig
immunogen
coformul
vaccin
construct
group
five
mice
immun
time
interv
combin
construct
alon
icp
construct
togeth
without
molecular
adjuv
deliv
singl
inject
site
splenocyt
collect
analysi
cellular
immun
respons
use
elispot
flow
cytometri
immun
group
saw
upward
trend
elispot
respons
addit
figur
function
profil
figur
figur
cell
analyz
flow
cytometri
mice
immun
alon
cell
respond
highli
phenotyp
enhanc
adjuv
group
figur
contrast
seen
figur
cell
respond
highli
pfn
phenotyp
also
enhanc
adjuv
group
mice
immun
icp
cell
respond
quit
similarli
icp
howev
adjuv
group
respons
preferenti
increas
figur
cell
respond
highli
howev
phenotyp
recapitul
adjuv
group
figur
mice
immun
cell
respond
highli
figur
phenotyp
chang
addit
wherea
cell
respond
highli
figur
expect
elispot
flow
cytometri
respons
mice
immun
empti
vector
control
pvax
alon
neglig
figur
function
liverloc
antigenspecif
cell
investig
use
construct
consist
produc
robust
cell
respons
mice
immun
time
interv
construct
without
one
week
final
immun
lymphocyt
isol
liver
spleen
immun
mice
phenotyp
function
capac
measur
use
flow
cytometri
elispot
assay
percentag
cell
liver
express
chemokin
receptor
import
traffick
liver
significantli
increas
without
codeliveri
addit
figur
express
cell
spleen
lower
figur
cell
liver
suggest
improv
traffick
liver
addit
seen
previous
addit
increas
antigenspecif
elispot
respons
spleen
figur
interestingli
also
liver
figur
investig
function
liverloc
cell
use
flow
cytometri
reveal
increas
percentag
tripl
posit
cell
figur
figur
cell
spleen
also
increas
percentag
figur
figur
cell
liver
vaccineinduc
antibodi
product
assay
immunofluoresc
cell
transfect
dna
vaccin
construct
two
day
post
transfect
cell
probe
postimmun
sera
mice
immun
respect
dna
construct
without
probe
fluoresc
tag
secondari
antibodi
mice
immun
show
posit
stain
indic
highest
antibodi
respons
icp
show
intermedi
antibodi
level
show
lowest
level
antibodi
induct
figur
addit
appear
alter
amount
detect
antibodi
bind
figur
howev
conclud
whether
antibodi
respons
import
observ
immun
unknown
whether
plasmodium
protein
would
avail
antibodi
bind
physiolog
relev
context
import
note
assay
show
presenc
antibodi
elicit
vaccin
provid
quantit
inform
antibodi
level
titer
assess
abil
dna
vaccin
construct
express
ls
malaria
antigen
protect
malaria
group
mice
immun
time
week
interv
combin
construct
alon
icp
construct
togeth
without
molecular
adjuv
challeng
week
later
intraven
deliveri
infecti
p
yoelii
sporozoit
blood
collect
daili
follow
sporozoit
inject
blood
smear
check
presenc
blood
stage
parasit
ie
patenc
figur
empti
vector
alon
immun
anim
visibl
blood
stage
parasit
day
challeng
total
anim
immun
dna
vaccin
deliv
without
adjuv
complet
protect
patenc
parasitemia
anim
protect
delay
full
day
total
anim
immun
combin
construct
addit
complet
protect
blood
stage
parasitemia
indic
steril
protect
group
figur
supplementari
tabl
exampl
blood
smear
group
show
presenc
blood
stage
parasit
pvax
alon
group
shown
figur
preerythrocyt
subunit
vaccin
clinic
develop
shown
limit
success
clinic
trial
sever
studi
report
cell
immun
ls
antigen
contribut
protect
immun
suggest
combin
vaccin
approach
target
multipl
lifecycl
stage
plasmodium
parasit
may
import
synthet
dna
deliv
adapt
electropor
ep
particularli
attract
vaccin
platform
target
ls
antigen
abil
induc
robust
cell
respons
clinic
studi
syndna
vaccin
deliv
ep
proven
highli
effect
small
larg
anim
model
infecti
diseas
cancer
demonstr
abil
drive
tissu
infiltr
popul
antigenspecif
cell
recent
year
dna
vaccin
hpv
hiv
zika
ebola
among
other
move
human
clinic
trial
present
novel
approach
use
synthet
dna
vaccin
ls
antigen
studi
without
plasmid
encod
molecular
adjuv
togeth
drive
antigenspecif
liver
associ
cell
strategi
achiev
impress
protect
bloodstag
diseas
virul
plasmodium
sporozoit
challeng
mous
model
ls
antigen
pfn
icp
express
across
plasmodia
make
entic
immun
target
could
provid
protect
multipl
speci
plasmodia
infect
human
well
allow
studi
murin
model
diseas
syndna
vaccin
platform
advantag
eas
deliv
cocktail
vaccin
target
multipl
antigen
well
codeliveri
molecular
adjuv
help
shape
final
immun
respons
design
syndna
vaccin
cassett
express
pfn
icp
figur
immun
mice
individu
cocktail
vaccin
construct
induc
strong
cellular
immun
respons
pfn
icp
induc
highest
elispot
respons
induc
elispot
respons
somewhat
lower
readili
detect
figur
intracellular
cytokin
stain
reveal
antigen
icp
induc
larg
cell
respons
pfn
induc
respons
other
induc
respons
figur
vaccin
cocktail
deliv
combin
antigenspecif
cell
respons
increas
compar
antigen
alon
figur
liver
resid
cell
respons
consid
import
provid
protect
respons
ls
antigen
proport
cell
express
increas
spleen
liver
anim
immun
plu
compar
antigen
alon
accompani
correspond
increas
product
antigenspecif
cell
liver
anim
immun
antigen
plu
figur
togeth
suggest
improv
traffick
vaccineinduc
antigenspecif
cell
liver
assess
impact
vaccineinduc
immun
plasmodium
infect
mice
immun
differ
combin
syndna
vaccin
antigen
without
challeng
week
later
intraven
inject
p
yoelii
sporozoit
anim
monitor
daili
develop
bloodstag
diseas
total
anim
immun
vaccin
antigen
cocktail
alon
protect
bloodstag
diseas
increas
protect
anim
immun
ls
antigen
plu
figur
suggest
increas
express
antigenspecif
product
liver
anim
immun
like
correspond
increas
traffick
vaccineinduc
antigenspecif
cell
liver
might
contribut
improv
protect
challeng
studi
requir
fulli
understand
role
regul
liver
associ
cell
respons
longev
immun
respons
induc
syndna
vaccin
target
liverstag
plasmodium
antigen
remain
determin
longlast
humor
cellular
immun
respons
induc
syndna
vaccin
target
pathogen
recent
describ
syndna
vaccin
express
ebola
viru
glycoprotein
induc
robust
humor
cellular
immun
cynomolgu
macaqu
minim
sign
contract
year
booster
immun
deliv
year
post
first
immun
result
typic
recal
respons
increas
antigenspecif
antibodi
titer
elispot
respons
effector
memori
em
effector
memori
ra
temra
domin
antigenspecif
express
cell
year
boost
provid
antigen
reexposur
recent
phase
clinic
trial
syndna
vaccin
express
premembran
envelop
prme
protein
zika
viru
induc
longlast
humor
cellular
immun
respons
human
total
particip
receiv
mg
dose
vaccin
remain
seroposit
week
last
immun
cellular
immun
respons
also
remain
quit
robust
week
last
vaccin
futur
studi
investig
memori
phenotyp
protect
potenti
longterm
immun
respons
syndna
plasmodium
liverstag
antigen
studi
demonstr
syndna
vaccin
target
liverstag
plasmodium
antigen
drive
antigenspecif
liverloc
cell
popul
studi
illustr
potenti
efficaci
syndna
vaccin
platform
target
liverstag
protein
provid
protect
malaria
infect
model
show
syndna
vaccin
target
pfn
icp
combin
alon
elicit
robust
cell
respons
well
product
antibodi
liverstag
malaria
use
molecular
adjuv
increas
immun
respons
vaccin
protect
anim
bloodstag
diseas
sporozoit
challeng
nonadjuv
vaccin
protect
anim
bloodstag
diseas
potenti
contributor
increas
protect
adjuv
group
increas
antigen
respons
liver
associ
cell
perhap
dosespar
effect
adjuv
previous
report
plasmid
result
group
show
enhanc
cytokin
polyfunction
addit
dose
adjuv
studi
remain
import
addit
focu
ls
antigen
compon
malaria
vaccin
warrant
potenti
combin
sporozoit
antigen
csp
rt
combin
might
particularli
interest
particular
seem
reason
approach
improv
current
impact
csp
target
vaccin
uniqu
studi
contribut
grow
literatur
collect
suggest
cellmedi
immun
addit
antibodi
studi
design
multicompon
antimalari
vaccin
well
support
continu
examin
liverstag
antigen
compon
prophylact
vaccin
